Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
C. Saldana
Institutions:
Centre Hospitalier Universitaire Henri-Mondor,
Assistance Publique – Hôpitaux de Paris,
Hôpitaux Universitaires Henri-Mondor
Observed institutions:
Autonomous University of Queretaro,
Centre Hospitalier Universitaire Henri-Mondor,
Assistance Publique – Hôpitaux de Paris,
Hôpitaux Universitaires Henri-Mondor,
Hôpital Saint-Louis
ORCID:
0000-0002-9768-6365
Observed ORCID:
0000-0002-9768-6365
OpenAlex ID:
A5035257097
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers
2017
·
M. Muller
, S. Ferlicot
, et al.
·
Clinical Genetics
·
160
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
2024
·
C.S. Groeneveld
, C. Pfister
, et al.
·
Annals of Oncology
·
38
Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group
2023
·
M. Guerin
, C. Miran
, et al.
·
Frontiers in Oncology
·
20
PDF
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
2020
·
Christian Pfister
, Valentin Harter
, et al.
·
Contemporary Clinical Trials Communications
·
17
PDF
735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study
2020
·
Z. Guillaume
, E. Colomba-Blameble
, et al.
·
Annals of Oncology
·
3
PDF
2961eP Carboplatin dose calculation based on renal function assessment using the MMB-eGFR formula: A proof-of-concept study
2025
·
E. Dominjon
, F. Pigneur
, et al.
·
Annals of Oncology
·
1
603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
2021
·
E. Colomba
, S.F. Jonas
, et al.
·
Annals of Oncology
·
1
How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool “Onco’nect®”
2018
·
M. Belhadj
, E. Kempf
, et al.
·
Annals of Oncology
·
1
Real-world outcomes of first-line (1L) Cabozantinib + Nivolumab (CaboNivo) for advanced Renal Cell Carcinoma (aRCC) according to nephrectomy/metastasectomy status: CaboCombo subgroup analysis
2026
·
A. Bamias
, A. Al-Olayan
, et al.
·
European Urology Open Science
PDF
Étude rétrospective des données cliniques, biologiques et d’imagerie de l’efficacité thérapeutique du 223Ra-Dichloride dans le cancer de la prostate
2025
·
E. Evangelista
, J. Demir
, et al.
·
Médecine Nucléaire
P192 CaboCombo: interim analyses from an international real-world study assessing the use of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced Renal Cell Carcinoma (aRCC)
2024
·
P. Barthélémy
, P. Gimel
, et al.
·
European Urology Open Science
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
2023
·
S. Oudard
, R. Ratta
, et al.
·
Annals of Oncology
PDF
Nephrectomy after complete response to immune checkpoint inhibitors for Metastatic Renal Cell Carcinoma (mRCC): A surgical challenge allowing favorable oncological outcomes
2021
·
G. Pignot
, A. Thiery-Vuillemin
, et al.
·
European Urology
723P Response to systemic therapy in fumarate hydratase (FH) mutated papillary renal cell carcinoma (pRCC): Is there a winner?
2020
·
L. Carril
, E. Colomba-Blameble
, et al.
·
Annals of Oncology
1549 Blood alcohol level in patients treated with gemcitabine and taxanes
2015
·
E. Assaf
, M. Verlinde-Carvalho
, et al.
·
European Journal of Cancer
Cinétique du PSA comme facteur prédictif de réponse par acétate d’abiratérone chez les patients atteints d’un cancer de la prostate en phase de résistance à la castration
2014
·
C. Saldana
, M. Chaubet-Houdu
, et al.
·
The French Journal of Urology
Renal Medullary Carcinoma: a Systematic Review
2014
·
C. Saldana
, G. Loganadane
, et al.
·
Annals of Oncology
Paclitaxel adjuvant en association avec une hormonothérapie versus une hormonothérapie seule chez les patients atteints d’un cancer de la prostate à haut risque de récidive après prostatectomie radicale
2013
·
C. Saldana
, L. Salomon
, et al.
·
The French Journal of Urology
Claudins in Normal and Lung Cancer State
2012
·
V. Morales-Tlalpan
, C. Saldana
, et al.
·
InTech eBooks
PDF
Show more works
View as search
Works count:
19
Citation count:
241
H-index:
4
I10-index:
4
Year
Topic
Type